Last 4.03 GBp
Change Today 0.00 / 0.00%
Volume 938.4K
As of 9:15 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

advanced oncotherapy plc (AVO) Snapshot

Open
4.03 GBp
Previous Close
4.03 GBp
Day High
4.03 GBp
Day Low
4.03 GBp
52 Week High
09/19/14 - 5.65 GBp
52 Week Low
06/4/14 - 2.45 GBp
Market Cap
41.4M
Average Volume 10 Days
1.6M
EPS TTM
-0.0069 GBp
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADVANCED ONCOTHERAPY PLC (AVO)

Related News

No related news articles were found.

advanced oncotherapy plc (AVO) Related Businessweek News

No Related Businessweek News Found

advanced oncotherapy plc (AVO) Details

Advanced Oncotherapy Plc, together with its subsidiaries, provides medical technology for cancer treatment in the United Kingdom and internationally. The company offers Linac Image Guided Hadron technology, the next generation of radiotherapy with precision guided protons for the treatment of cancer; and Single Dose Intraoperative Radiotherapy technology for the treatment of early stage breast cancer. It is also involved in the development and rental of healthcare related properties. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy Plc in September 2012. Advanced Oncotherapy Plc is based in London, the United Kingdom.

13 Employees
Last Reported Date: 06/29/14

advanced oncotherapy plc (AVO) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 68.8K GBP
Executive Chairman and Member of Audit Commit...
Total Annual Compensation: 189.0K GBP
Compensation as of Fiscal Year 2013.

advanced oncotherapy plc (AVO) Key Developments

Advanced Oncotherapy Plc Signs an Agreement to Lease Harley Street Location

Advanced Oncotherapy Plc announced that it has signed an agreement to lease a Harley Street location, which will become the UK's first Proton Therapy Centre using the company's LIGHT System. The centre will become a hub where patients from London, the rest of the UK and others further afield can have their cancers effectively treated with a proton therapy system. Advanced Oncotherapy has signed an agreement with Howard de Walden Estates Limited granting a 50 year lease for the whole of 141 Harley Street and part of 143 Harley Street to the Company. The properties, which comprise approximately 8,000 sq ft, will be converted for use as a Proton Therapy Centre, and will house the first LIGHT machine to be constructed and operated in the UK. The grant of the lease is subject to the relevant planning and other statutory consents being obtained for the redevelopment of the buildings. The total cost of the redevelopment will be borne by Howard de Walden Estates and is estimated at between £6-7 million. Work will start in July 2015, with the property expected to be handed over to Advanced Oncotherapy by the end of 2016 when the first LIGHT System will be ready, enabling patients to start treatments in 2017. The company also has an agreement with SUNY Upstate Medical University Hospital in Syracuse, Central New York State to build a US based proton therapy facility using the LIGHT system. The facility in Harley Street will be constructed in parallel with the US installation, and the Company is in early discussions with private healthcare providers in the UK to operate in this location.

Advanced Oncotherapy Announces the Manufacture of the First CCL (Coupled Cavity Linac) Module

Advanced Oncotherapy announced that the manufacture of the first CCL (Coupled Cavity Linac) module has been successfully completed. This required a complex design procedure and sophisticated manufacturing process achievable only through a successful collaboration between high-level physicists, scientists, engineers and industrial experience and expertise. The CCL accelerating structures are an essential part of the LIGHT proton therapy system. They consist of a series of cells which accelerate the protons from energies of 37.5 Mega-electron Volts (MeV) to the full 230MeV required to treat all radiosensitive tumours found in a typical clinical setting.

Advanced Oncotherapy Sign Agreement SUNY Upstate Medical University Hospital to Install the First Light System in the Highly-Sought After Area of Syracuse, Central New York State

Advanced Oncotherapy announced that the SUNY Upstate Medical University Hospital ('SUNY'), has signed an agreement to exclusively work with Advanced Oncotherapy to install the first LIGHT system in the highly-sought after area of Syracuse, Central New York State. The agreement extends the collaboration previously signed a Letter of Intent to establish a relationship to build a three-room proton treatment facility incorporating the first operational LIGHT system in North America. SUNY is set to become Advanced Oncotherapy's US hub for research and development, manufacture and treatment using the next generation proton therapy technology for treating cancers. In addition SUNY and Advanced Oncotherapy will develop a clinical training and sales facility on the same site, which could ultimately supply LIGHT machines to all of the Americas.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVO:LN 4.03 GBp 0.00

AVO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVO.
View Industry Companies
 

Industry Analysis

AVO

Industry Average

Valuation AVO Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 353.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED ONCOTHERAPY PLC, please visit www.advancedoncotherapy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.